Certara (Certara) ROCE % : -1.83% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Certara ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Certara's annualized ROCE % for the quarter that ended in Dec. 2023 was -1.83%.

Certara ROCE % Historical Data

The historical data trend for Certara's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara ROCE % Chart

Certara Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

1.92

-2.30

1.03

2.53

-2.22

Certara Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial														2.53	2.16	3.82	-13.20	-1.83

Certara ROCE % Calculation

Certara's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-32.227	/	( ( (1572.922 - 103.158)	+	(1563.14 - 130.023) )	/ 2 )
	=	-32.227	/	( (1469.764	+	1433.117)	/ 2 )
	=	-32.227	/	1451.4405
	=	-2.22 %

Certara's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-26.056	/	( ( (1526.821 - 105.427)	+	(1563.14 - 130.023) )	/ 2 )
	=	-26.056	/	( ( 1421.394	+	1433.117 )	/ 2 )
	=	-26.056	/	1427.2555
	=	-1.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Certara (NAS:CERT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Certara ROCE % Related Terms

Thank you for viewing the detailed overview of Certara's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Certara (Certara) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540

Website

https://www.certara.com

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.

Executives

Richard M. Traynor	officer: See Remarks	1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Leif E Pedersen	officer: President, Software	10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Eran Broshy	director	C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
Patrick F Smith	officer: PRESIDENT, INTEGRATED DRUG DEV	C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
John E Gallagher	officer: CHIEF FINANCIAL OFFICER	BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p.	10 percent owner	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight	director	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine	director	2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905